

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

O'Brien, S;Borland, ML;Cotterell, E;Armstrong, D;Babl, F;Bauert, P;Brabyn, C;Garside, L;Haskell, L;Levitt, D;McKay, N;Neutze, J;Schibler, A;Sinn, K;Spencer, J;Stevens, H;Thomas, D;Zhang, M;Oakley, E;Dalziel, SR

Title:

Australasian bronchiolitis guideline

Date:

2019-01-01

Citation:

O'Brien, S., Borland, M. L., Cotterell, E., Armstrong, D., Babl, F., Bauert, P., Brabyn, C., Garside, L., Haskell, L., Levitt, D., McKay, N., Neutze, J., Schibler, A., Sinn, K., Spencer, J., Stevens, H., Thomas, D., Zhang, M., Oakley, E. & Dalziel, S. R. (2019). Australasian bronchiolitis guideline. *Journal of Paediatrics and Child Health*, 55 (1), pp.42-53. <https://doi.org/10.1111/jpc.14104>.

Persistent Link:

<https://hdl.handle.net/11343/284227>

Title: Australasian Bronchiolitis Guideline

Abstract:

Aim: Bronchiolitis is the commonest lower respiratory tract disorder in infants aged less than 12 months of age and research has demonstrated there is substantial variation in practice patterns despite treatment being well defined. In order to align and improve consistency of management of bronchiolitis, an evidence based guideline was developed for the Australasian population.

Method: The guideline development committee included representation from emergency and paediatric specialty medical and nursing personnel in addition to geographical representation across Australia and New Zealand; rural, remote and metropolitan. Formulation of the guideline included identification of population, intervention, comparator, outcomes and time questions and associated with an extensive literature search from 2000-2015. Evidence was summarised and graded utilising the NHMRC and GRADE methodology and consensus within the guideline group sought using nominal group technique principles to formulate the clinical practice recommendations. The guideline was reviewed and endorsed by key paediatric health bodies

Results: The guideline consists of a usable clinical interface for bedside functionality supported by evidence summary and tables. The GRADE and NHMRS processes provided a systematic and transparent process to review and assess the literature resulting in a guideline which is relevant to the management of bronchiolitis in the Australasian setting.

Conclusion: This is the first robust Australasian acute paediatric guideline and provides clear guidance for the management of the vast majority of patients seen in Australasian EDs and general paediatric wards with bronchiolitis.

Key Words:

Bronchiolitis; Guideline; Management; Paediatric; Respiratory

Introduction

Bronchiolitis is the commonest lower respiratory tract disorder in infants less than 12 months of age.^(1, 2) Each year approximately 13,500 Australian infants with bronchiolitis are admitted to hospital, accounting for 56% of all admissions to hospital for infants.⁽³⁾ In New Zealand 1-

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/jpc.14104](https://doi.org/10.1111/jpc.14104)

2% of infants with bronchiolitis require hospital admission, with those living in the most deprived socioeconomic areas, Maori and Pacific infants, having increased rates.⁽⁴⁾

While evidence-supported treatment is focussed on therapies to ensure hydration and respiratory support,^(5, 6) substantial practice variations remain in Australasian hospitals.⁽⁷⁾ For example, up to 48% of infants admitted to hospitals in Australasia receive treatment for which there is Cochrane level evidence of no benefit.⁽⁸⁾ Although high quality international clinical practice guidelines for bronchiolitis exist from the United States and the United Kingdom^(9, 10) they do not take into account the latest evidence or the Australian and New Zealand context in terms of health care systems and epidemiology.⁽¹¹⁾ Thus we determined a need for a robust locally applicable guideline to summarise the latest evidence and provide a practical guide for clinicians in Australia and New Zealand.

To address this important high volume condition, we undertook a systematic literature review followed by the development of the guideline. The systematic review of the literature used National Health and Medical Research Council (NHMRC) strength of recommendations classification system⁽¹²⁾ and Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology⁽¹³⁾ (Table 1), with wide stakeholder consultation. The resulting guideline is the first Australasian acute care paediatric guideline to be developed to this robust standard.

Methods

The Guideline Steering Committee comprised five members (paediatric emergency medicine physicians (SRD, EO, MB), a regional paediatrician (EC), and a paediatric nurse (SO) from the Paediatric Research in Emergency Departments International Collaborative (PREDICT) executive committee. PREDICT is Australasia's acute paediatric research network, and includes members from over 30 hospitals, including all Australasian tertiary paediatric hospitals.⁽¹⁴⁾ Invitations were then sent to all Australasian paediatric hospitals, relevant medical and nursing professional societies and colleges, and identified local content experts, asking for nominations to join the Guideline Development Committee (GDC) which finally comprised 22 individuals including; general paediatricians, paediatric respiratory physicians, paediatric and general emergency medicine physicians, paediatric intensive care physicians,

paediatric nurse practitioners, paediatric and emergency nurses from metropolitan and non-metropolitan centres, in New Zealand and Australia (representing seven of the eight states and territories). The process was funded by an NHMRC Centre of Research Excellence grant (GNT 1058560) as a key knowledge translation priority and the full Guideline methodology has been described elsewhere.⁽¹⁵⁾

Scope

The guideline specifically addressed care in both the emergency department (ED) and on general wards for the management of bronchiolitis, in order to influence the majority of patients who present to hospital with bronchiolitis. It specifically excluded management in primary care and intensive care units (ICU) as ward based hospitalisation is the primary determinant of health care expenditure for bronchiolitis⁽¹⁶⁾ and only a small proportion of patients admitted to hospital with bronchiolitis require ICU management.⁽¹⁷⁾

Aim

Development of an evidence-based clinical practice guideline for infants presenting to and hospitalised in Australasia.

Target audience

Staff working in Australasian ED's and general paediatric wards areas.

Process

The GDC identified 33 key clinical questions in the Patient, Intervention, Comparison, Outcome, time (PICOt) format relevant to the management of bronchiolitis (Table 1).

A literature search was performed, with the assistance of a medical information specialist, from 1 January 2000 to 17 December 2015 of the following electronic databases: Ovid MEDLINE, Ovid Embase, PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Review library and Cochrane Database of Systematic Reviews (CDSR) (Appendix 1). This was to identify appropriate literature for the clinical questions. Following removal of duplicates, each title and abstract was reviewed by one of the five members of the Steering Committee for possible inclusion. The resulting manuscripts were then sourced and made available to members of the GDC.

The evidence was summarised in NHMRC and GRADE tables, with clinical recommendations based on NHMRC ⁽¹²⁾ and GRADE methodology ⁽¹³⁾(Table 2). Where possible, for those clinical questions involving interventions, the evidence used to make recommendations was based on systematic reviews and randomised controlled trials.

All recommendations and evidence tables were reviewed by the GDC and consensus sought using nominal group technique principles.

A draft guideline was produced consisting of both a bedside version plus a full guideline including the evidence tables. The draft was circulated to all Australasian tertiary paediatric hospitals, medical and nursing professional societies and colleges, and identified local content experts for wide consultation. All feedback was reviewed by the GDC, with only minor adjustments required for the final guideline.

Results

The literature search identified 12,535 manuscripts, of which 8,722 were assessed for possible inclusion in the guideline after initial review of the titles and abstracts (Appendix 2).

Five evidence based recommendations were made with regards to diagnosis and 28 with regards to management of infants presenting to, and admitted to hospital with bronchiolitis (Table 3). These have been formatted into a bedside resource for staff (Table 4 and 5).

Key recommendations for practice change in the guideline include:

Routine investigations: Routine testing of urine or blood is not recommended for the management of infants with bronchiolitis (Table 3, recommendation 4).^(10, 18-25) However, both retrospective and prospective cohort studies of infants with bronchiolitis have shown an increased risk of concurrent urinary tract infections (UTIs) in infants aged less than two months of age.⁽²⁰⁾ Based on this evidence, the final recommendations in the guideline state

that in infants less than two months of age with bronchiolitis, with a fever and clinical uncertainty, clinicians may consider collecting a urine sample for microscopy, culture and sensitivity looking for the presence of a UTI (Table 3, recommendation 4).

Viral testing and patient cohorting: A systematic review of 82 studies, with heterogeneity of study design and outcome, demonstrated a lack of evidence for any clinical benefit from routine viral testing.⁽¹⁸⁾ Based on this evidence the final recommendations state that routine use of viral testing is not recommended for any clinically relevant end-points, including cohorting of bronchiolitis patients (Table 3, recommendation 5). Further research is recommended to determine if patient cohorting based on virological results has added advantage over routine contact precautions in reducing hospital transmission.

Salbutamol: Data regarding the administration of beta-2 agonists such as salbutamol (with the exclusion of adrenaline) in infants with bronchiolitis comes from one Cochrane Systematic Review,⁽²⁶⁾ and three systematic reviews and guidelines.^(10, 27, 28) There is high level evidence (NHMRC A, GRADE strong) demonstrating no benefit of beta 2 agonists in infants with bronchiolitis for the outcomes of admission to hospital, oxygen saturation or length of stay. Furthermore, there is low quality evidence of adverse events from use of beta-2-agonists in bronchiolitis. The evidence is consistent across all ages in the first 12 months of life with a sensitivity analysis showing no significant subgroup effect in the cohort over 6 of months of age.⁽²⁶⁾

Based on this evidence the final recommendations in the guideline do not recommend routine use of beta-2-agonists (Table 3, recommendation 8).

Nebulised adrenaline: Data regarding the administration of adrenaline/epinephrine in infants with bronchiolitis comes from one Cochrane Systematic Review⁽²⁹⁾ and two systematic reviews and guidelines^(27, 28) and a recent high quality RCT.⁽³⁰⁾

Evidence from the Cochrane Systematic Review⁽²⁸⁾ and the recent high quality RCT⁽³⁰⁾ does not suggest that administering adrenaline/epinephrine in inpatients with bronchiolitis changes hospital length of stay or readmission rates.

Based on this evidence the final recommendations in the guideline do not recommend routine use of nebulised adrenaline (Table 3, recommendation 9).

Hypertonic saline: Data regarding the administration of nebulised hypertonic saline in infants with bronchiolitis is based on one Cochrane Systematic Review (11 RCTs)⁽³¹⁾, a further nine additional RCTs⁽³²⁻⁴⁰⁾, and five subsequent systematic reviews/meta-analyses.⁽⁴¹⁻⁴⁵⁾ Infants admitted to hospital with bronchiolitis and administered nebulised hypertonic saline have a reduced length of stay of 0.45 days (95%CI=-0.74 to -0.14 days; 15 studies, n=1,922). However there is considerable heterogeneity in this overall result ($I^2=78\%$). Removal of two studies with overall length of stay considerably longer than current clinical practice in Australia and New Zealand, and with a primary outcome definition considerably different than that used locally for discharge (no respiratory signs or symptoms for 12 hours), partially explains the heterogeneity and results in a pooled estimate suggesting no effect. Furthermore, analysis restricted to the four largest trials, all at lower risk of bias, again suggests no benefit.⁽⁴³⁾

While there is weak evidence of reduced admission rates following the use of nebulised hypertonic saline, there is heterogeneity in the treatment regimens used, and a suggestion that one to two dose regimens are ineffective. The routine use of nebulised hypertonic saline in the ED to reduce admissions is not supported by the current evidence and nebulised hypertonic saline should only be used in infants with bronchiolitis as part of an RCT.

Based on this evidence the final recommendations in the guideline do not recommend routine use of nebulised hypertonic saline (Table 3, recommendation 10).

Glucocorticoids: Data regarding the administration of glucocorticoids in infants with bronchiolitis comes from one Cochrane systematic review⁽⁴⁶⁾, three subsequent systematic reviews and guidelines^(10, 27, 28), and two further RCTs.^(47, 48) Infants with bronchiolitis administered glucocorticoids do not have reduced rates of hospitalisation, or differences in length of stay.

Based on this evidence the final recommendations in the guideline do not recommend routine use of glucocorticoids (Table 3, recommendation 11).

Antibiotics: Two Cochrane systematic reviews^(49, 50) and a single RCT of 40 infants⁽⁵¹⁾ show no benefit of antibiotics for treating bronchiolitis, in terms of hospital length of stay and hospital readmission rates⁽⁴⁹⁾ or persisting symptoms⁽⁵⁰⁾. The risk of secondary bacterial infection in bronchiolitis is very low and there is potential harm of antibiotics use from adverse reactions and increased antibiotic resistance.

Based on this evidence the final recommendations in the guideline do not recommend routine use of antibiotics (Table 3, recommendation 20).

Oxygen and respiratory support: The benefit of supplemental oxygen therapy has not been specifically studied; rather there are assumptions about the benefits of oxygen based on first principles and observational studies. Studies have predominantly investigated duration of oxygen administration and feeding difficulties as a gauge of effectiveness.^(28, 52-54) There is no evidence of the benefit of oxygen in children without hypoxia and low level evidence that maintaining an oxygen saturation of more than 91% prolongs length of stay.^(28, 52-58) The absolute oxygen saturation at which to commence supplemental oxygen therapy has ranged in studies from 90 to 94%. To date, no RCTs have reported long-term neurodevelopmental outcomes in babies with bronchiolitis. Due to the lack of this long-term evidence on safety with oxygen saturation targets of less than 92% the GDC recommends commencing oxygen therapy below this level. (Table 3, recommendation 12)

For the outcome of admission to hospital there is moderate evidence that oxygen saturation levels affects the decision to admit independently of other factors including signs of respiratory distress.^(28, 57, 58) For the important outcome of readmission oxygen level saturations do not affect readmissions to hospital.^(52, 57, 58)

A prospective observational study⁽⁵⁹⁾ with moderate quality evidence demonstrates that continuous monitoring of pulse oximetry increases hospital length of stay (Table 3, recommendation 13).

There have been limited studies on high flow, humidified nasal cannula oxygen (HFNC) in children with bronchiolitis during inpatient stay outside of the ICU⁽⁶⁰⁾ and all provide low to

very low level evidence for the benefit of HFNC. (Table 3, recommendation 14). Larger RCTs are pending.

Discussion

Clinical guidelines are a familiar tool to the Australasian health care setting and there is broad agreement to create joint national emergency medicine guidelines.⁽⁶¹⁾ Guidelines can contribute to health care becoming more consistent, efficient and based on scientific evidence.⁽⁶²⁾ In order to provide robust recommendations, guidelines should be informed by a systematic review and critical appraisal of the literature.⁽⁶³⁾ We present the first such project for an acute paediatric condition in an Australasian setting and in doing so we have made 31 key recommendations for the diagnosis and management of infants presenting to and admitted into hospital with bronchiolitis (Table 3). These recommendations are evidence based with a clear link to the strength of the evidence behind each recommendation.

Bronchiolitis is the most common reason for infants to be admitted into hospital in Australia and New Zealand, and throughout the developed world.^(9, 10) Despite the frequency of the presentation, and a literature review of over 12,000 titles, it is somewhat disappointing that only five recommendations were rated GRADE “strong,” sixteen rated “conditional” and ten rated “weak.” There is a strong evidence base that intravenous and nasogastric routes are suitable for non-oral rehydration; there is also strong evidence for not administering beta-2-agonists, adrenaline, glucocorticoids, and physiotherapy. Yet even amongst these interventions the evidence base is rated “weak” for a number of the sub-groups. A notable evidence gap is the possible synergy between glucocorticoids and adrenaline which is a high priority for a definitive RCT.⁽⁶⁴⁾ The evidence gaps identified by the systematic review and critical appraisal will be useful for setting out the agenda for bronchiolitis research.

A key strength of the guideline is that it has been undertaken by a multidisciplinary team with a clear understanding of the local challenges of clinical practice. Furthermore, members came from predominantly emergency and general paediatric backgrounds, the two craft groups most closely involved with bronchiolitis management. This will ensure the relevance of the bedside guidance to local clinicians (Appendix 3). In addition, the evidence

recommendations have used both an international appraisal tool (GRADE)⁽⁶⁵⁾ as well as a local standard (NHMRC)⁽¹²⁾, again ensuring local relevance.

The final recommendations are broadly consistent with the American Academy of Paediatrics (AAP)⁽⁹⁾ evidence based recommendations, undertaken a few years prior, and those from the National Institute of Clinical Excellence (NICE)⁽¹⁰⁾ in the United Kingdom, undertaken at the same time as the Australasian guideline. All three guidelines strongly recommend against the use of beta-2-agonists, adrenaline, and glucocorticoids. Different oxygen limits (90% vs. 92% vs. 94%) remain recommended in the literature and require further research.

A strength of our process for developing this guideline was the use of nominal group principles and confidential voting using a Likert scale to ascertain consensus for each recommendation and practice point.^(66, 67) A median score of seven was set as consensus of agreement.⁽⁶⁷⁾ The structure for the draft guideline was agreed by all members of the Guideline Development Committee. Formal feedback was sought from consultations with stakeholders which included clinical leads of general paediatrics and EDs at Australian and New Zealand tertiary paediatric hospitals, consumers and Australian and New Zealand professional medical and nursing colleges to ensure relevance of the final guideline to the Australasian emergency and paediatric ward setting. The professional Colleges all provided written approval of the guideline and agreement to use this information in the dissemination, increasing the validity of this as a clinical tool.

The guidelines do have a number of limitations. Firstly, bronchiolitis is a clinical diagnosis. As such the experience of the individual clinician is likely to have a key role in terms of their confidence in subsequently following the recommended management. Secondly, while the AAP definition of bronchiolitis includes infants up to two years of age, the large RCTs conducted within North America often restrict inclusion criteria to the first episode of wheezing in an infant.^(64, 68) In contrast the large RCTs conducted in Australasia include up to 30% of infants with a second or subsequent episode of bronchiolitis.^(69, 70) Finally, the guideline specifically excluded intensive care patients and the recommendations need to be interpreted with caution in this population.

Conclusion

In conclusion, this is the first robust Australasian acute paediatric guideline on bronchiolitis. It provides clear guidance for the management of patients seen in Australasian EDs and general paediatric wards with bronchiolitis. The future challenge is to translate and maintain this knowledge into everyday clinical practice.

Conflict of Interest

The authors declare that they have no competing interests.

References

1. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. *Pediatr Infect Dis J*. 2003;22 (2 Suppl):S76-S82.
2. Wohl M, Chernick V. State of the art: bronchiolitis. *Am Rev Respir Dis* 1978;118:759-81.
3. Roche P, Lambert S, Spencer J. Surveillance of viral pathogens in Australia: Respiratory syncytial virus. *Communicable Diseases Intelligence* [Internet]. 2003 March 2003; 27(1):[117-22 pp.]. Available from: <http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-cdi-2003-cdi2701-j.htm-cdi2701j.htm>.
4. Craig E, Anderson P, Jackson C. The Health Status of children and young people in Auckland DHB. Auckland: New Zealand Child and Youth Epidemiology Service. 2008.
5. Davison. C, Ventre. K. M, Luchetti. M, Randolph. A. G. Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis. *Pediatric Critical Care Medicine*. 2004;5(5):482-9.
6. Smyth R, Openshaw P. Bronchiolitis. *Lancet*. 2006;368:312-22.
7. Babl FE, Sherif N, Neutze J, Borland M, Oakley E. Bronchiolitis management in pediatric emergency departments in Australia and New Zealand: a PREDICT study. *Pediatric Emergency Care*. 2008;24(10):656-8.
8. Oakley E, Brys T, Borland M, Neutze J, Dalziel S. Medication use in infants admitted with bronchiolitis at 7 Australian and New Zealand centres. *International Conference on Emergency Medicine*; Hong Kong 2014.
9. American Academy of Pediatrics Subcommittee on D, Management of B. Diagnosis and management of bronchiolitis. *Pediatrics*. 2006;118(4):1774-93.
10. Ricci V, Delgado Nunes V, Murphy MS, Cunningham S, Guideline Development G, Technical T. Bronchiolitis in children: summary of NICE guidance. *Bmj*. 2015;350:h2305.
11. Australian Indigenous Health Info Net. Review of respiratory disease among Indigenous peoples. 2005 5 April 2016. Available from: <http://www.healthinonet.ecu.edu.au/chronic-conditions/respiratory/reviews/our-review>.
12. National Health and Medical Research Council. NHMRC: additional levels of evidence and grades for recommendations for developers of guidelines. *National Health and Medical Research Council*; 2009.
13. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. *Bmj*. 2008;336(7650):924-6.
14. Babl FE, Borland ML, Ngo P, Acworth J, Krieser D, Pandit S, et al. Paediatric Research in Emergency Departments International Collaborative (PREDICT): first steps towards the development of an Australian and New Zealand research network. *Emergency Medicine Australia*. 2006;18(2):143-7.
15. O'Brien S, Wilson S, Gill FJ, Cotterell E, Borland ML, Oakley E, et al. The management of children with bronchiolitis in the Australasian hospital setting: development of a clinical practice guideline. *BMC Medical Research Methodology*. 2018;18(1):22.
16. Al-Shehri MA, Sadeq A, Quli K. Bronchiolitis in Abha, Southwest Saudi Arabia: viral etiology and predictors for hospital admission. *West Afr J Med*. 2005;24(4):299-304.
17. Somech R, Tal G, Gilad E, Mandelberg A, Tal A, Dalal I. Epidemiologic, socioeconomic, and clinical factors associated with severity of respiratory syncytial virus infection in previously healthy infants. *Clinical Pediatrics*. 2006;45(7):621-7.
18. Bordley WC, Viswanathan M, King VJ, Sutton SF, Jackman AM, Sterling L, et al. Diagnosis and testing in bronchiolitis: a systematic review. *Arch Pediatr Adolesc Med*. 2004;158(2):119-26.

19. Dayan PS, Roskind CG, Levine DA, Kuppermann N. Controversies in the management of children with bronchiolitis. *Clinical Pediatric Emergency Medicine*. 2004;5(1):41-53.
20. Elkhunovich MA, Wang VJ. Assessing the utility of urine culture testing in febrile infants 2-12 months of age with bronchiolitis. *Pediatric Emergency Care*. 2012;28 (10):1093.
21. Fares M, Mourad S, Rajab M, Rifai N. The use of C-reactive protein in predicting bacterial co-infection in children with bronchiolitis. *North American Journal of Medical Sciences*. 2011;3(3):152-6.
22. Laham JL, Breheny PJ, Gardner BM, Bada H. Procalcitonin to predict bacterial coinfection in infants with acute bronchiolitis: a preliminary analysis. *Pediatric Emergency Care*. 2014;30(1):11-5.
23. Luu R, DeWitt PE, Reiter PD, Dobyns EL, Kaufman J. Hyponatremia in children with bronchiolitis admitted to the pediatric intensive care unit is associated with worse outcomes. *Journal of Pediatrics*. 2013;163(6):1652-6.e1.
24. Ralston S, Hill V, Waters A. Occult serious bacterial infection in infants younger than 60 to 90 days with bronchiolitis: a systematic review. *Arch Pediatr Adolesc Med*. 2011;165(10):951-6.
25. Titus MO, Wright SW. Prevalence of serious bacterial infections in febrile infants with respiratory syncytial virus infection. *Pediatrics*. 2003;112(2):282-4.
26. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. *Cochrane Database of Systematic Reviews* 2014;CD001266 (6).
27. Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. *Ital J Pediatr*. 2014;40:65.
28. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. *Pediatrics*. 2014;134(5):e1474-e502.
29. Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, et al. Epinephrine for bronchiolitis. *Cochrane Database of Systematic Reviews*. 2011(6):CD003123.
30. Skjerven HO, Hunderi JO, Brugmann-Pieper SK, Brun AC, Engen H, Eskedal L, et al. Racemic adrenaline and inhalation strategies in acute bronchiolitis. *New England Journal of Medicine*. 2013;368(24):2286-93.
31. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. *Cochrane Database of Systematic Reviews*. 2013;7:CD006458.
32. Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. *Thorax*. 2014;69(12):1105-12.
33. Florin TA, Shaw KN, Kittick M, Yakscoe S, Zorc JJ. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. *Jama, Pediatr*. 2014;168(7):664-70.
34. Jacobs JD, Foster M, Wan J, Pershad J. 7% Hypertonic saline in acute bronchiolitis: a randomized controlled trial. *Pediatrics*. 2014;133(1):e8-13.
35. Khanal A, Sharma A, Basnet S, Sharma PR, Gami FC. Nebulised hypertonic saline (3%) among children with mild to moderately severe bronchiolitis - a double blind randomized controlled trial. *BMC Pediatrics*. 2015;15(1).

36. Ojha AR, Mathema S, Sah S, Aryal UR. A comparative study on use of 3% saline versus 0.9% saline nebulization in children with bronchiolitis. *Journal of Nepal Health Research Council*. 2014;12(26):39-43.
37. Sharma BS, Gupta MK, Rafik SP. Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trial. *Indian Pediatrics*. 2013;50(8):743-7.
38. Silver AH, Esteban-Cruciani N, Azzarone G, Douglas LC, Lee DS, Liewehr S, et al. 3% Hypertonic saline versus normal saline in inpatient bronchiolitis: A randomized controlled trial. *Pediatrics*. 2015;136(6):1036-43.
39. Teunissen J, Hochs AH, Vaessen-Verberne A, Boehmer AL, Smeets CC, Brackel H, et al. The effect of 3% and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial. *European Respiratory Journal*. 2014;44(4):913-21.
40. Wu S, Baker C, Lang ME, Schragger SM, Liley FF, Papa C, et al. Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial. *Jama, Pediatr*. 2014;168(7):657-63.
41. Badgett RG, Vindhyal M, Stirnaman JT, Gibson CM, Halaby R. A living systematic review of nebulized hypertonic saline for acute bronchiolitis in infants. *Jama, Pediatr*. 2015;169(8):788-9.
42. Chen YJ, Lee WL, Wang CM, Chou HH. Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: An updated meta-Analysis. *Pediatrics and Neonatology*. 2014;55(6):431-8.
43. Maguire C, Cantrill H, Hind D, Bradburn M, Everard ML. Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. *BMC Pulmonary Medicine*. 2015;15(1).
44. Mitchell MD, Schast AP, Umscheid CA. Nebulized hypertonic saline treatment for infants with bronchiolitis (Structured abstract). *Health Technology Assessment Database [Internet]*. 2013; (2). Available from: <http://onlinelibrary.wiley.com/doi/10.1111/hta.12104>.
45. Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized hypertonic saline for acute bronchiolitis: A systematic review. *Pediatrics*. 2015;136(4):687-701.
46. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. *Cochrane Database of Systematic Reviews*. 2013;6:CD004878.
47. Alansari K, Sakran M, Davidson BL, Ibrahim K, Alrefai M, Zakaria I. Oral dexamethasone for bronchiolitis: a randomized trial. *Pediatrics*. 2013;132(4):e810-6.
48. Jartti T, Nieminen R, Vuorinen T, Lehtinen P, Vahlberg T, Gern J, et al. Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode. *Journal of Allergy and Clinical Immunology*. 2015;135(3):691-8.e9.
49. Farley R, Spurling GK, Eriksson L, Del Mar CB. Antibiotics for bronchiolitis in children under two years of age. *Cochrane Database of Systematic Reviews*. 2014;10:CD005189.
50. McCallum GB, Morris PS, Chang AB. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. *Cochrane Database of Systematic Reviews*. 2012;12:CD009834.
51. Beigelman A, Isaacson-Schmid M, Sajol G, Baty J, Rodriguez OM, Leege E. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. *Journal of Allergy and Clinical Immunology [Internet]*. 2014. Available from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2222.2014.02828.x>.

52. Cunningham S, McMurray A. Observational study of two oxygen saturation targets for discharge in bronchiolitis. *Archives of Disease in Childhood*. 2012;97(4):361-3.
53. Mitchell MD, Schast AP, Umscheid CA. Oxygen saturation discharge thresholds for infants admitted with bronchiolitis (Structured abstract). *Health Technology Assessment Database [Internet]*. 2013; (2). Available from: <http://onlinelibrary.wiley.com/doi/10.1111/hta.12104>.
54. Unger S, Cunningham S. Effect of oxygen supplementation on length of stay for infants hospitalized with acute viral bronchiolitis. *Pediatrics*. 2008;121(3):470-5.
55. Choi J, Claudius I. Decrease in emergency department length of stay as a result of triage pulse oximetry. *Pediatric Emergency Care*. 2006;22(6):412-4.
56. Hendaus MA, Jomha FA, Alhammadi AH. Pulse oximetry in bronchiolitis: Is it needed? *Therapeutics and Clinical Risk Management*. 2015;11:1573-8.
57. Schroeder AR, Marmor AK, Pantell RH, Newman TB. Impact of pulse oximetry and oxygen therapy on length of stay in bronchiolitis hospitalizations. *Arch Pediatr Adolesc Med*. 2004;158(6):527-30.
58. Schuh S, Freedman S, Coates A, Allen U, Parkin PC, Stephens D, et al. Effect of oximetry on hospitalization in bronchiolitis: a randomized clinical trial. *Jama*. 2014;312(7):712-8.
59. Kaditis AG, Katsouli G, Malakasioti G, Kaffe K, Gemou-Engesaeth V, Alexopoulos EI. Infants with viral bronchiolitis demonstrate two distinct patterns of nocturnal oxyhaemoglobin desaturation. *Acta Paediatrica, International Journal of Paediatrics*. 2015;104(3):e106-e11.
60. Beggs S, Wong ZH, Kaul S, Ogden KJ, Walters JA. High-flow nasal cannula therapy for infants with bronchiolitis. *Cochrane Database of Systematic Reviews*. 2014;1:CD009609.
61. Dalton S, Babl FE. Paediatric emergency guidelines: could one size fit all? *Emergency medicine Australasia : EMA*. 2009;21(1):67-70.
62. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Potential benefits, limitations, and harms of clinical guidelines. *BMJ : British Medical Journal*. 1999;318(7182):527-30.
63. *Medicine*. 10.
64. Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al. Epinephrine and Dexamethasone in Children with Bronchiolitis. *New England Journal of Medicine*. 2009;360(20):2079-89.
65. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *Journal of clinical epidemiology*. 2011;64(4):383-94.
66. James D, Warren-Forward H. Research methods for formal consensus development. *Nurse Researcher*. 2015;22(3):35-40.
67. Rolls KD, Elliott D. Using consensus methods to develop clinical practice guidelines for intensive care: The Intensive Care Collaborative project. *Australian Critical Care*. 2008;21(4):200-15.
68. Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R, Reeves SD, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. [Erratum appears in *N Engl J Med*. 2008 Oct 30;359(18):1972. Note: Mahajan, Prashant [corrected to Mahajan, Prashant]]. *New England Journal of Medicine*. 2007;357(4):331-9.
69. Franklin D, Dalziel S, Schlapbach LJ, Babl FE, Oakley E, Craig SS, et al. Early high flow nasal cannula therapy in bronchiolitis, a prospective randomised control trial (protocol): A Paediatric Acute Respiratory Intervention Study (PARIS). *BMC Pediatrics*. 2015;15(1):183.

70. Oakley E, Borland M, Neutze J, Acworth J, Krieser D, Dalziel S, et al. Nasogastric hydration versus intravenous hydration for infants with bronchiolitis: a randomised trial. *Lancet Respir Med*. 2013;1(2):113-20.

Acknowledgments

PREDICT would like to acknowledge the input and feedback provided in the consultation phase by stakeholders to ensure relevance of the final guideline to the Australasian emergency and paediatric ward setting. Formal feedback was received from: Australasian College for Emergency Medicine, The Australian Paediatric Society, The Royal Australasian College of Physicians, South Island Alliance Child Health Service, Children's Healthcare Australasia, Australian College of Emergency Nursing Ltd, The Australian College of Children and Young People's Nurses, College of Child and Youth Nurses New Zealand, College of Emergency Nurses New Zealand, Family Advisory Committee Royal Children's Hospital Melbourne, New South Wales Office of Kids and Families, New South Wales Paediatric Clinical Nurse Consultant Group, Paediatric Department Christchurch Hospital, Paediatric Respiratory Department Starship Children's Health, Royal New Zealand College of Urgent Care, Professor Innes Asher, Associate Professor Simon Craig, Dr Joshua Osowicki, Dr Arjun Rao, Associate Professor Mike Starr and Dr Emma Tavender. PREDICT would also like to acknowledge the support and assistance provided by Ms Catherine Wilson, PREDICT Research Network Co-ordinator, Dr Sarah Dalton and Dr David Johnson.

The project was funded by a National Health and Medical Research Council Centre of Research Excellence grant for paediatric emergency medicine (GNT1058560) administered by the Murdoch Children's Research Institute.

Appendix 1:

Australasian Bronchiolitis Guideline – Literature search strategy

Data Sources	MEDLINE (OvidSP); EMBASE (OvidSP); PubMed; The Cochrane Library; CINAHL(EBSCO)
MeSH terms (MEDLINE OvidSP)	Population bronchiolitis/ bronchiolitis, viral/ respiratory syncytial viruses/ respiratory syncytial virus, human/ respiratory syncytial virus infections/ AND Intervention / Area of interest natural history/ epidemiology/ exp "reproducibility of results"/ "severity of illness index"/ diagnosis, differential/ physical examination/ exp auscultation/ blood pressure determination/ exp palpation/ percussion/ pulse/ exp vital signs/ exp *respiratory tract infections/ risk factors/ "length of stay"/ patient admission/ patient discharge/ exp intensive care units, pediatric/

	respiratory care units/ morbidity/ prevalence/ exp mortality/ exp diagnostic imaging/ radiography, thoracic/ exp hematologic tests/ urinalysis/ nasal lavage fluid/ emergency service, hospital/ asthma/ or hypersensitivity, immediate/ exp albuterol/ad, tu epinephrine/ad,tu bronchodilator agents/ad, tu steroids/ad, tu exp cholinergic antagonists/ or receptors, adrenergic, beta-2/ exp anti-inflammatory agents/ exp adrenal cortex hormones/ leukotriene antagonists/ saline solution, hypertonic/ad, tu exp aerosols/ exp sodium chloride/ exp "nebulizers and vaporizers"/ exp oxygen inhalation therapy/ *oxygen/ad, st exp oximetry/ home care services/ home care services, hospital-based/ exp blood gas analysis/ continuous positive airway pressure/ positive pressure respiration/ positive end respiratory pressure/ exp physical therapy modalities/
--	--

	physical therapy specialty/ exp physiotherapy/ suction/ administration, intranasal/ exp fluid therapy/ rehydration solutions/ enteral feeding/ parenteral feeding/ intubation, gastrointestinal/ exp bacterial infections/ exp otitis media/ exp meningitis/ exp *antibacterial agents/tu exp sepsis/ exp urinary tract infections/ tracheitis/ infection control/ exp primary prevention/ patient isolation/
Keywords (PubMed/Cochrane Library)	Population (bronchiolit* OR wheez* OR (Respiratory Syncytial Virus*) OR rsv AND Intervention / Area of interest history OR epidemiolog* OR "severity of illness" OR "disease severity" OR scoring system* OR diagnosis OR physical exam* OR auscultation OR "blood pressure" OR palpation* OR percussion OR pulse OR vital sign* OR Respiratory Tract Infection* OR risk factor* OR "length of stay" OR admission OR discharge OR "intensive care" OR ICU OR "respiratory care" OR morbidit* OR prevalence OR mortalit* OR "diagnostic imaging" OR ((chest OR thorac*) AND (x-ray* OR xray* OR "x ray" OR radiograph*)) OR ((hematolog* OR haematolog* OR blood OR virolog* OR urine) AND (test OR tests OR exam* OR investigation*)) OR urinalys* OR "nasal lavage" OR ((nose OR nasal) AND (mucosa OR mucus)) OR emergency department* OR asthma* OR atopy OR atopic OR hypersensitiv* OR salbutamol OR albuterol OR ventolin OR levalbuterol OR adrenalin* OR epinephrin* OR beta2 adrenergic* OR beta2 agonist* OR ics OR corticosteroid* OR cortico steroid*OR cortico-steroid* OR glucocorticoid* OR gluco corticoid* OR gluco-corticoid* OR montelukast OR bronchodilat* OR steroid OR steroids OR cholinergic antagonist* OR cholinergic receptor* OR anti inflammatory


	agent* OR adrenal cortex hormone* OR leukotriene antagonist* OR leukotriene receptor* OR "hypertonic saline" OR (("sodium chloride" OR saline) AND (nebuliz* OR nebulis* OR vaporiz* OR vaporis* OR aerosol* OR intranasal OR "intra nasal" OR intra-nasal OR nasal)) OR oxygen OR "home oxygen" OR ((oximetry OR oximeter*) AND ("reproducibility of results" OR reliability OR validity OR function* OR technical specification* OR percutaneous measurement* OR blood gas analys*)) OR CPAP OR "continuous positive airway pressure" OR "positive pressure respiration" OR "positive end respiratory pressure" OR supplementa* oxygen OR "oxygen saturation" OR oxygen therap* OR oxygen treatment* OR physical therap* OR physiotherap* OR ((nasal* OR nose OR naso) AND (suction* OR toilet OR irrigation)) OR suction* OR saline drop* OR "nasal saline" OR "intranasal saline" OR deep suction* OR ((non oral OR oral) AND (feed* OR hydration OR fluid* OR solution* OR therap*)) OR azithromycin OR fluid therap* OR intravenous infusion* OR "non oral" OR rehydrat* OR "enteric feeding" OR "parenteral nutrition" OR "parenteral feeding" OR "enteral nutrition" OR oral* administ* OR bacterial infection* OR "otitis media" OR meningitis OR antibacterial agent* OR anti-bacterial agent* OR anti bacterial agent* OR antimicrobial agent* OR anti-microbial agent* OR anti microbial agent* OR antibiotic* OR sepsis OR septic OR urinary tract infection* OR tracheitis OR serious bacterial infection* OR "infection control" OR "primary prevention" OR isolation OR "patient care"
Search dates	The following databases were searched on the 17th December 2015 for references back to 1 January 2000: Medline (Ovid), Embase (Ovid) and The Cochrane Library. Ebsco Host Cinahl was searched back to 2000 for studies relating to chest physiotherapy and bronchiolitis only. PubMed was searched back to 2013 to capture E-pubs not available in Medline and back to 2000 to capture journals not indexed in Medline.
Other information sources checked	Reference lists of included studies were searched to identify additional relevant papers (i.e. snowballing references)
Inclusion criteria	(Publication type = clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or controlled clinical trial or guideline or meta analysis or practice guideline or randomized controlled trial or "review" or systematic reviews) or exp evidence-based medicine/ English language yr="2000 -current" age limit = ("newborn infant (birth to 1 month)" or "infant (1 to 23 months)") or infant* or newborn* or neonat* or babies or baby
Exclusion criteria	(Publication type = case reports or comment or editorial or letter) or exp bronchiolitis obliterans/ or bronchiolitis obliterans

Appendix 2

Australasian Bronchiolitis Guideline Prisma Diagram

*PubMed was searched back to 2013 to capture E-pubs not available in Medline and back to 2000 to capture journals not indexed in Medline

**CINAHL was searched for studies relating to chest physiotherapy and bronchiolitis only



Appendix 3 - Australasian-bronchiolitis-bedside-clinical-guideline

<http://www.predict.org.au/download/Australasian-bronchiolitis-bedside-clinical-guideline.pdf>

Learning Points – Australasian Bronchiolitis Guideline

'What is already known on this topic:'

- Bronchiolitis is the most common reason for infants <1 year of age to be admitted to hospital.
- Wide variation in management of bronchiolitis exists across Australia and New Zealand, with up to 48% of infants admitted into hospital receiving treatment for which there is high quality (Cochrane level evidence) of no benefit.
- To date, there have been no high quality acute paediatric guidelines developed across Australia and New Zealand.

'What this paper adds:'

- This is the first high-quality acute paediatric guideline developed for use across Australia and New Zealand.
- Thirty three questions related to core management of infants with bronchiolitis were assessed according to GRADE and NHMRC strength of evidence guidelines.
- 30 research questions were also identified for future research.

Table I:

Patient, Intervention, Comparison, Outcome, time (PICOT) questions relevant to the management of bronchiolitis addressed in the guideline.

<u>Number</u>	<u>Question</u>
1	In infants presenting to hospital what factors in history and physical examination contribute to a differential diagnosis of bronchiolitis?
2	In infants presenting to hospital with bronchiolitis, what are the risk factors for admission or severe disease (e.g. prolonged length of hospital stay, intensive care unit (ICU) admission, and death)?
3	In infants presenting to hospital or hospitalised with bronchiolitis, does performing a CXR beneficially change medical management or clinically relevant end-points?
4	In infants presenting to hospital or hospitalised with bronchiolitis, does performing laboratory tests (blood and/or urine) beneficially change medical management or clinically relevant end-points?
5	In infants presenting to hospital or hospitalised with bronchiolitis, does performing virological investigations beneficially change medical management or clinically relevant end-points?
6	For infants presenting to hospital or hospitalised with bronchiolitis, does use of a bronchiolitis scoring system beneficially change medical management or clinically relevant end-points?
7	For infants presenting to hospital or hospitalised with bronchiolitis, what criteria should be used for safe discharge?
8a. i)	In infants presenting to hospital or hospitalised with bronchiolitis, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
8a. ii)	In older infants presenting to hospital or hospitalised with bronchiolitis, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
8b. i)	In infants presenting to hospital or hospitalised with bronchiolitis, with a personal or family history of atopy, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
8b. ii)	In older infants presenting to hospital or hospitalised with bronchiolitis, with a second or subsequent episode/s of bronchiolitis or wheeze, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
9	In infants presenting to hospital or hospitalised with bronchiolitis, does administration of adrenaline / epinephrine (nebulisation, IM or IV) improve clinically relevant end-points?
10	In infants presenting to hospital or hospitalised with bronchiolitis, does administration of nebulised hypertonic saline improve clinically relevant end-points?
11a.	In infants presenting to hospital or hospitalised with bronchiolitis, does administration of systemic or local glucocorticoids (nebulisation, oral, IM or IV) improve clinically relevant end-points?
11b.	In infants presenting to hospital or hospitalised with bronchiolitis, with a positive response to Beta2 Agonists, does administration of systemic or local glucocorticoids (nebulisation, oral, IM or IV) improve clinically relevant end-points?

11c.	In infants presenting to hospital or hospitalised with bronchiolitis, does administration of the combination of systemic or local glucocorticoids (nebulisation, oral, IM or IV) and adrenaline improve clinically relevant end-points?
12a.	In infants presenting to hospital or hospitalised with bronchiolitis, does administration of supplemental oxygen improve clinically relevant end-points?
12b.	In infants presenting to hospital or hospitalised with bronchiolitis, what level of oxygen saturation should lead to commencement or discontinuation of supplemental oxygen to improve clinically relevant end-points?
13.	In infants hospitalised with bronchiolitis does continuous monitoring of pulse oximetry beneficially change medical management or clinically relevant end-points?
14.	In infants hospitalised with bronchiolitis does the use of heated humidified high flow oxygen, or air, via nasal cannula improve clinically relevant end-points?
15.	In infants hospitalised with bronchiolitis, does chest physiotherapy improve clinically relevant end-points?
16a.	In infants hospitalised with bronchiolitis, does suctioning of the nose or naso pharynx improve clinically relevant end-points?
16b.	In infants hospitalised with bronchiolitis, does deep suctioning in comparison to superficial suctioning beneficially improve clinically relevant end-points?
17	In infants hospitalised with bronchiolitis, does the use of nasal saline drops improve clinically relevant end-points?
18.	In infants hospitalised with bronchiolitis, does the use of bubble CPAP improve clinically relevant end-points?
19.	In infants hospitalised with bronchiolitis, is provision of home oxygen a safe alternative for management?
20a.	In infants presenting to hospital or hospitalised with bronchiolitis, does the use of antibiotic medication improve clinically relevant end-points?
20b.	In infants presenting to hospital or hospitalised with bronchiolitis, does the use azithromycin medication improve clinically relevant end-points?
20c.	In infants presenting to hospital or hospitalised with bronchiolitis, does the use of antibiotic medication in infants who are at risk of developing bronchiectasis, improve clinically relevant end-points?
21a.	In infants presenting to hospital or hospitalised with bronchiolitis, does the use of non-oral hydration improve clinically relevant end-points?
21b.	In infants presenting to hospital or hospitalised with bronchiolitis, what forms of non-oral hydration improve clinically relevant end-points
21c.	In infants presenting to hospital or hospitalised with bronchiolitis, does limiting the volume of non-oral hydration impact on clinical relevant end-points?
22	In infants presenting to hospital or hospitalised with bronchiolitis, does infection control practices improve clinically relevant end-points?

Table II: National Health and Medical Research Council (NHMRC) strength of recommendation definitions and Grading of Recommendations Assessment, Development and Evaluation (GRADE) quality of evidence definitions used in the guideline process to make a final recommendation.

2a: NHMRC strength of recommendation definitions (3)

A	Body of evidence can be trusted to guide practice
B	Body of evidence can be trusted to guide practice in most situations
C	Body of evidence provides some support for recommendation(s) but care should be taken in its application
D	Body of evidence is weak and recommendation must be applied with caution

2b: GRADE quality of evidence definitions (9)

High quality	Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low Quality	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality	Any estimate of effect is very uncertain

Table III: Evidence based recommendations for bronchiolitis management.

Diagnosis

1. Infants can be diagnosed with bronchiolitis if they have an upper respiratory tract infection followed by onset of respiratory distress with fever, and one or more of: cough, tachypnoea, retractions and diffuse crackles or wheeze on auscultation.

(NHMRC: C, GRADE: Weak)

2. Clinicians should consider as risk factors for more serious illness: gestational age less than 37 weeks; chronological age at presentation less than 10 weeks; exposure to cigarette smoke; breast feeding for less than two months; failure to thrive; having chronic lung disease; having chronic heart and/or chronic neurological conditions; being Indigenous ethnicity, and should take these into account when managing infants with bronchiolitis.

(NHMRC: C, GRADE: Conditional)

3. Routine CXR is not recommended as it does not improve management in infants presenting with simple bronchiolitis, and may lead to treatments of no benefit.

(NHMRC: D, GRADE: Conditional)

4. There is no role for blood tests in managing infants presenting to hospital and hospitalised with bronchiolitis. Routine bacteriological testing of blood and urine is not recommended.

(NHMRC: D, GRADE: Conditional)

In infants less than two months of age presenting to hospital or hospitalised with bronchiolitis with a temperature over 38 degrees, there is a low risk of urinary tract infection (UTI). If clinical uncertainty exists clinicians may consider collecting a urine sample for microscopy, culture and sensitivity looking for the concurrent presence of UTI.

5. In infants with bronchiolitis, routine use of viral testing is not recommended for any clinically relevant end-points, including cohorting of bronchiolitis patients.

(NHMRC: C, GRADE: Conditional)

Management

6. For infants presenting to hospital or hospitalised with bronchiolitis, there is insufficient evidence to recommend the use of a scoring system to predict need for admission or hospital length of stay.

(NHMRC: D, GRADE: Weak)

7. Oxygen saturations, adequacy of feeding, age (infants younger than eight weeks), and lack of social support should be considered at the time of discharge as a risk for representation. There is insufficient evidence to recommend absolute discharge criteria for infants attending the ED, or hospitalised with bronchiolitis

(NHMRC: Practice Point, GRADE: Weak)

8a. Do not administer beta 2 agonists to infants, less than or equal to 12 months of age, presenting to hospital or hospitalised with bronchiolitis.

(NHMRC: A, GRADE: Strong)

8b. Do not administer beta 2 agonists to infants, less than or equal to 12 months of age, presenting to hospital or hospitalised with bronchiolitis, with a personal or family history of atopy.

(NHMRC: D, GRADE: Weak)

9. Do not administer adrenaline/epinephrine to infants presenting to hospital or hospitalised with bronchiolitis.

(NHMRC: B, GRADE: Strong)

10. Do not administer nebulised hypertonic saline in infants presenting to hospital or hospitalised with bronchiolitis.

(NHMRC: D, GRADE: Conditional)

11a. Do not administer systemic or local glucocorticoids to infants presenting to hospital or hospitalised with bronchiolitis.

(NHMRC: B, GRADE: Strong)

11b. Do not administer systemic or local glucocorticoids to infants presenting to hospital or hospitalised with bronchiolitis, with a positive response to beta 2 agonists.

(NHMRC: D, GRADE: Weak)

11c. Do not administer a combination of systemic or local glucocorticoids and adrenaline/epinephrine to infants presenting to hospital or hospitalised with bronchiolitis.

(NHMRC: D, GRADE: Weak)

12a. Consider the use of supplemental oxygen in the treatment of hypoxic (oxygen saturations less than 92%) infants with bronchiolitis.

(NHMRC: C, GRADE: Conditional)

12b. In uncomplicated bronchiolitis oxygen supplementation should be commenced if the oxygen saturation level is sustained at a level less than 92%. At oxygen saturation levels of 92% or greater, oxygen therapy should be discontinued.

(NHMRC: C, GRADE: Conditional)

13. Routine use of continuous pulse oximetry is not required for medical management of non-hypoxic (saturations greater than or equal to 92%) infants not receiving oxygen, or stable infants receiving oxygen.

(NHMRC: C, GRADE: Conditional)

14. High Flow Nasal Cannulae Oxygen (HFNC) in bronchiolitis can be considered in the inpatient setting on infants with bronchiolitis with hypoxia (oxygen saturations less than 92%). Its use in children without hypoxia should be limited to the RCT setting only.

(NHMRC: C, GRADE: Conditional)

15. Chest physiotherapy is not recommended for routine use in infants with bronchiolitis.

(NHMRC: B, GRADE: Strong)

16a. Nasal suction is not recommended as routine practice in the management of infants with bronchiolitis. Superficial nasal suction may be considered in those with moderate disease to assist feeding.

(NHMRC: D, GRADE: Conditional)

16b. Deep nasal suction for the management of bronchiolitis is not recommended.

(NHMRC: D, GRADE: Conditional)

17. Routine nasal saline drops are not recommended. Trial of intermittent saline drops may be considered at time of feeding.

(NHMRC: Practice Point, GRADE: Weak)

18. Nasal CPAP therapy for infants with bronchiolitis may be considered for the management of infants.

(NHMRC: C, GRADE: Conditional)

19. After a period of observation, infants at low risk for severe bronchiolitis can be considered for discharge on home oxygen as part of an organised 'Home Oxygen Program' which has clear 'Return to Hospital' advice.

(NHMRC: C, GRADE: Conditional)

20a. Do not use antibiotics to treat infants with bronchiolitis.

(NHMRC: B, GRADE: Conditional)

20b. Do not use azithromycin for treatment of infants admitted to hospital with bronchiolitis.

(NHMRC: B, GRADE: Conditional)

20c. Do not use azithromycin for treatment of infants admitted to hospital with bronchiolitis who are at risk of developing bronchiectasis.

(NHMRC: C, GRADE: Conditional)

21a. Supplemental hydration is recommended for infants who cannot maintain hydration orally.

(NHMRC: Practice Point, GRADE: Weak)

21b. Both NG and IV routes are acceptable means for non-oral hydration in infants admitted to hospital with bronchiolitis.

(NHMRC: B, GRADE: Strong)

21c. There is insufficient evidence to recommend a specific proportion of maintenance fluid. There is a risk of fluid overload therefore judicious and vigilant use of hydration fluid is and regular clinical review is recommended. Isotonic fluid is recommended.

(NHMRC: Practice Point, GRADE: Weak)

22. Hand hygiene is the most effective intervention to reduce hospital acquired infections and is recommended. There is inadequate evidence for benefits in cohorting infants with bronchiolitis.

(NHMRC: D, GRADE: Weak)

Table IV: Bedside bronchiolitis assessment aid

Initial Assessment			
This table is meant to provide guidance in order to stratify severity. The more symptoms the infant has in the mod-severe categories, the more likely they are to develop severe disease.			
	Mild	Moderate	Severe
Behaviour	Normal	Some/intermittent irritability	Increasing irritability and/or lethargy Fatigue
Respiratory Rate	Normal – mild tachypnoea	Increased respiratory rate	Marked increase or decrease in respiratory rate
Use of accessory muscles	Nil to mild chest wall retraction	Moderate chest wall retractions Tracheal tug Nasal flaring	Marked chest wall retractions Marked tracheal tug Marked nasal flaring
Oxygen saturation / oxygen requirement	O ₂ saturations greater than 92% (in room air)	O ₂ saturations 90 - 92% (in room air)	O ₂ saturations less than 90% (in room air) Hypoxemia, may not be corrected by O ₂
Apnoeic episodes	None	May have brief apnoea	May have increasingly frequent or prolonged apnoea
Feeding	Normal	May have difficulty with feeding or reduced feeding	Reluctant or unable to feed

Table V: Bedside bronchiolitis management aid

Initial Management The main treatment of bronchiolitis is supportive. This involves ensuring appropriate oxygenation and fluid intake.			
	Mild	Moderate	Severe
Likelihood of Admission	Suitable for discharge Consider risk factors	Likely admission, may be able to be discharged after a period of observation Management should be discussed with a local senior physician	Requires admission and consider need for transfer to an appropriate children's facility/PICU Threshold for referral is determined by local escalation policies but should be early
Observations Vital signs (respiratory rate, heart rate, O ₂ saturations, temperature)	Adequate assessment in ED prior to discharge (minimum of two recorded measurements or every four hours as per local hospital guidelines and EWT)	Hourly - dependent on condition (as per local hospital guidelines and EWT)	Hourly with continuous cardiorespiratory (including oximetry) monitoring and close nursing observation - dependent on condition (as per local hospital guidelines and EWT)
Hydration/Nutrition	Small frequent feeds	If not feeding adequately (less than 50% over 12 hours), administer NG or IV hydration	If not feeding adequately (less than 50% over 12 hours), or unable to feed, administer NG or IV hydration
Oxygen saturation / oxygen requirement	Nil requirement	Administer O₂ to maintain saturations greater than or equal to 92%	Administer O₂ to maintain saturations greater than or equal to 92%
Respiratory Support		Consider HFNC if a trial of NPO₂ is ineffective	Consider HFNC or CPAP
Disposition/Escalation	Consider further medical review if early in the illness and any risk factors are present or if child develops increasing severity after discharge	Decision to admit should be supported by clinical assessment, social and geographical factors and phase of illness	Consider escalation if severity does not improve. Consider ICU review/ admission or transfer to local centre with paediatric HDU/ICU capacity if: - Severity does not improve - Persistent desaturations

			- Significant or recurrent apnoea's associated with desaturations
Parental Education	Provide advice on the expected course of illness and when to return (worsening symptoms and inability to feed adequately) Provide Parent Information Sheet	Provide advice on the expected course of illness and when to return (worsening symptoms and inability to feed adequately) Provide Parent Information Sheet	Provide advice on the expected course of illness Provide Parent Information Sheet

PICU = paediatric intensive care unit, EWT = early warning tool, NG = Nasogastric, IV = Intravenous, NPO2 = Nasal Prong Oxygen, HFNC = heated humidified high flow oxygen/air via nasal cannulae, CPAP = continuous positive airway pressure, HDU = high dependency unit.

Title: Australasian Bronchiolitis Guideline

Type of Manuscript: Original Article

Authors:

Ms Sharon O'Brien, BNurs, Paed Cert, RN

Princess Margaret Hospital for Children
Child & Adolescent Health Service
Roberts Road Subiaco, WA 6008
Perth, Western Australia

School of Nursing, Midwifery & Paramedicine
Faculty of Health Sciences
Curtin University
Perth, Western Australia
Email: sharon.obrien@health.wa.gov.au

A/Prof Meredith Louise Borland, MBBS, FACEM

Princess Margaret Hospital for Children
Child & Adolescent Health Service
Roberts Road Subiaco, WA 6008
Perth, Western Australia

Divisions of Paediatric and Emergency Medicine
School of Medicine
University of Western Australia
Perth WA 6840
Email: meredith.borland@health.wa.gov.au

A/Prof Elizabeth Cotterell, MBBS Dip. Paed FRACP, MPH

Associate Professor, Paediatrics
School of Rural Medicine
University of New England
Armidale NSW 2351
Email: liz.cotterell@une.edu.au

A/Prof David Armstrong, MD, FRACP

Department of Respiratory Medicine, Monash Children's Hospital,
Clayton, Victoria, Australia

Department of Paediatrics, Monash University,
Clayton, Victoria, Australia.

Email: David.Armstrong@monashhealth.org

Associate Professor Franz Babl, MD, MPH, DMedSc, FRACP, FAAP, FACEP

Emergency Department, Royal Children's Hospital, Parkville, Victoria, Australia

Murdoch Children's Research Institute, Parkville, Victoria, Australia

University of Melbourne, Parkville, Victoria, Australia

Email: Franz.Babl@rch.org.au

Dr Paul Bauert, OAM, FAMA, BSc MBBS, FRACP

Paediatrician

Royal Darwin Hospital

Darwin, Northern Territory, Australia

Email: paulbauert@gmail.com

Dr Christine Brabyn, BSc, MBChB, FRACP, FACEM

Waikato Emergency Department

Waikato New Zealand

Email: Christine.Brabyn@waikatodhb.health.nz

Dr Lydia Garside FRCPCH, FRACP, FAFRM

General Paediatrics

Sydney Children's Hospital,

Randwick, NSW 2031

Email: lydia.garside@health.nsw.gov.au

Ms Libby Haskell, BHSc (Nursing), MN, NP

Children's Emergency Department

Starship Children's Hospital

Private Bag 92024

Auckland 1142

New Zealand

Email: libbyh@adhb.govt.nz

Dr David Levitt, MBBS, FRACP

Director of Paediatric Medicine and Dermatology
Lady Cilento Children's Hospital
South Brisbane QLD 4101

Senior Lecturer

University of Queensland

Email: David.Levitt@health.qld.gov.au

Ms Nicola McKay RN, BN, MN, Grad Cert Paed Oncology

Paediatric Clinical Nurse Consultant
Western Sydney Local Health District and NSW
Children's Healthcare Network Western Region
Email: nicola.mckay@health.nsw.gov.au

Dr Jocelyn Neutze, MBChB, FRACP, FACEM

Kidzfirst Middlemore Hospital,
Otahuhu, Auckland, New Zealand
Email: Jocelyn.Neutze@middlemore.co.nz

Associate Professor Andreas Schibler MD, FCICM

Paediatric Intensive Care Staff Specialist FCICM - Paediatric Intensive Care Unit
Medical Lead Paediatric Critical Care Research Group (PCCRG)
Lady Cilento Children's Hospital and The University of Queensland
Lady Cilento Children's Hospital
South Brisbane Qld 4101
Email: a.schibler@uq.edu.au

Dr Kam Sinn, MBBS, FRACP

Emergency Department
The Canberra Hospital
Yamba Drive
Canberra, ACT, 2605
Email: sinn.kam@gmail.com

Dr Janine Spencer MBBS, Dip TM&H, Dip FMed, FRACP

Department of Paediatrics

South Metropolitan Health Services

Fiona Stanley Hospital

Murdoch, Perth, Western Australia

Email: Janine.spencer@health.wa.gov.au

Ms Helen Stevens, RN, BN

Clinical Nurse Consultant, Paediatrics

Hunter New England Health/Children's Healthcare Network (Northern) NSW

Armidale, NSW

Email: Helen.stevens@hnehealth.nsw.gov.au

Dr David Thomas, MBBS, FRACP, MD, MEd

Women's & Children's Hospital

72 King William Road

North Adelaide SA 5006

Email: david.thomas@sa.gov.au

Dr Michael Zhang, FACEM, FRACP, MBBS, MmedStat

Emergency Department,

John Hunter Hospital

Lookout Rd

New Lambton Heights, NSW, 2305

Email: Michael.zhang@hnehealth.nsw.gov.au

A/Prof Ed Oakley, MBBS, FACEM

Royal Children's Hospital Melbourne

Murdoch Children's Research Institute

50 Flemington Rd, Parkville VIC 3052

University of Melbourne

Cnr Grattan Street & Royal Parade

University of Melbourne VIC 3010

Paediatric Emergency Medicine Centre of Research Excellence

Email: ed.oakley@rch.org.au

Dr Stuart R Dalziel, MBChB, FRACP, PhD

Children's Emergency Department

Starship Children's Hospital

Private Bag 92024

Auckland 1142

New Zealand

Email: sdalziel@adhb.govt.nz

On behalf of the Paediatric Research in Emergency Departments International Collaborative (PREDICT) network, Australasia.

Author to whom correspondence about the manuscript should be sent:

Ms Sharon O'Brien

Princess Margaret Hospital for Children

Child & Adolescent Health Service

Roberts Road Subiaco, WA 6008

Perth, Western Australia

Email: sharon.obrien@health.wa.gov.au

Mobile: (+61) 0409 104 665